---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040758"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:53:54.051718+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics CEO Kaye steps down; Ian Smith named interim; FY 2024 net loss $89M

## Summary
- CEO Edward Kaye steps down March 19; Ian F. Smith appointed Interim CEO; Arthur Tzianabos named Interim Executive Chair.
- Full year 2024 net loss $89.0M ($1.65/share) vs $104.7M loss in 2023; revenue $36.6M from Acadia collaboration (vs $8.8M prior year).
- Cash, equivalents, and marketable securities $246.7M at Dec 31, 2024; plus $165M upfront from Biogen collaboration funds operations to mid-2028.
- Phase 3 registrational study (EMPEROR) of zorevunersen for Dravet syndrome on track to initiate in Q2 2025.
- Board initiates search for permanent CEO; Kaye remains as advisor and director.

## SEC filing metadata
- accession: 0000950170-25-040758
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/0000950170-25-040758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/stok-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040758
- JSON: https://secwatch.observer/filing/0000950170-25-040758.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040758.txt

## Key facts
- Executive change
  Edward Kaye departed as Chief Executive Officer at Stoke Therapeutics, Inc..
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: On March 16, 2025, Dr. Edward Kaye, M.D., 75, the Company’s Chief Executive Officer (“CEO”) and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s CEO, effective March 19, 2025 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/0000950170-25-040758-index.htm
- Executive change
  Arthur Tzianabos was appointed as Interim Executive Chair at Stoke Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Executive Chair
  source text: Also in connection with Dr. Kaye’s transition, effective as of the Transition Date, the Board appointed Arthur Tzianabos, 61, currently Chair of the Board, as Interim Executive Chair of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/0000950170-25-040758-index.htm
- Executive change
  Ian F. Smith was appointed as Interim Chief Executive Officer at Stoke Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: Effective as of the Transition Date, the Board appointed Ian F. Smith, 59, a director on the Board, to succeed Dr. Kaye as Interim Chief Executive Officer (“Interim CEO”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017025040758/0000950170-25-040758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.